The Non-Financial Ledger: What This Actually Costs

C4 Therapeutics is a clinical-stage drug company. That language sounds sterile, but what it describes is a company whose entire purpose is to keep cancer patients alive. The drug at the center of this case, CFT7455, was designed for people with multiple myeloma and non-Hodgkin lymphoma. These are not abstract diagnoses. Multiple myeloma destroys bone marrow. Non-Hodgkin lymphoma spreads through the lymphatic system. The patients in those clinical trials were sick, scared, and putting their bodies on the line for a drug that might help them or might not. They had no idea that the man hired to analyze the data generated by their suffering was watching his brokerage app.

Clinical trial integrity depends on a closed system of trust. Pharmaceutical companies, regulators, and the public all operate on the assumption that the people inside that system follow the rules. Biostatisticians occupy one of the most sensitive positions in that system. They see the actual numbers before anyone else. They know if the drug is working before the company’s own executives are allowed to trade. That privilege exists to protect patients and investors alike. Wang’s consulting engagement gave him the kind of access most people on Wall Street would trade their careers for, and the SEC alleges he did exactly that.

Consider what the public market represents: thousands of ordinary investors, retirement accounts, people who looked at C4’s story and decided to take a chance on a company trying to cure cancer. When an insider buys shares ahead of a positive announcement, those investors are buying into a rigged game. They pay more for shares they should have been able to buy at fair prices. The market’s basic promise, that no one gets a sneak peek, was broken the moment Wang allegedly loaded that clinical data into a spreadsheet and opened his brokerage account in the same sitting.

And then there is the institutional damage. Every time a case like this surfaces, every clinical-stage company that relies on contractors and consultants has to ask itself: who else has done this? The chilling effect on research partnerships, on the flow of talent into sensitive data roles, on investor confidence in the integrity of pre-announcement periods, is real and it is not priced into anyone’s settlement check.

Wang dissolved Precision Clinical Consulting in February 2025, filing a Certificate of Dissolution with the State of New Jersey. The SEC complaint, filed in January 2026, makes clear that Precision still held assets in an active brokerage account at the time of filing. The dissolution paperwork did not make the profits disappear. It just made it look like the entity that earned them no longer existed.

Legal Receipts: The Documents That Seal It

Every quote below is taken verbatim from SEC Complaint Case 1:26-cv-10140, filed January 14, 2026, in the United States District Court for the District of Massachusetts. These are the words of the SEC and, in some instances, of Wang’s own signed agreements.

“At 11:05am on November 20, 2023, Wang responded to the 9:02am email confirming for C4’s senior communications manager that he extracted the relevant data into a spreadsheet. Moments later, at 11:25am, Wang purchased 2,000 shares of C4 common stock.” SEC Complaint, Para. 53-54

“Wang, on behalf of TechData, signed a consulting agreement with C4 (the ‘Consulting Agreement’)… By signing the Consulting Agreement, Wang expressly acknowledged that ‘Confidential Information may contain material non-public information concerning C4[]’ and that he was ‘aware of the restrictions imposed by U.S. federal and state securities laws… on persons in possession of material non-public information concerning a company whose securities are publicly traded that prohibit purchasing or selling securities of that company.'” SEC Complaint, Para. 31

“In August 2023, Wang completed C4’s mandatory insider trading course. This course covered ‘an overview of US insider trading laws and provide[d] practical information to help employees comply’ by ‘break[ing] down the complex concept of insider trading into easily understood elements.’ Specifically, for example, the course provided examples of what constitutes insider trading, such as ‘a company employee buying company stock before a major product announcement is made publicly.'” SEC Complaint, Para. 40-41

“Wang’s two individual accounts and the Precision account each made all of their C4 stock purchases on December 12, 2023, mere hours before the Public Announcement. Prior to November 20, 2023, the Wang Accounts never traded in C4 stock.” SEC Complaint, Para. 60-61

Societal Impact Mapping: Who Pays When Insiders Win

Public Health

Insider trading in clinical-stage pharmaceutical companies carries a specific category of public health harm that goes beyond the financial.

• Clinical trials depend on trust. Patients who enroll in trials at companies like C4 do so believing that their data will be handled with integrity and used only to advance treatment. When insiders exploit that data for personal gain, the ethical framework sustaining patient participation is damaged, even if the breach is never disclosed to the patients themselves.
• CFT7455 was in development for multiple myeloma and non-Hodgkin lymphoma, two cancers with significant mortality rates and limited treatment options. Any scandal that undermines investor confidence in C4 at a critical moment in the drug’s development pathway has the potential to affect the company’s ability to fund continued trials, access future capital, and bring the drug to patients who may have no other options.
• The broader clinical research ecosystem, where biostatisticians and data analysts routinely access trial results under confidentiality agreements, faces an integrity question every time a case like this becomes public. Institutional review boards, patients, and advocacy organizations all have reason to demand stronger controls over data access, and those controls cost time and money that ultimately slows the pace of drug development.

Economic Inequality

Insider trading is fundamentally a wealth transfer from ordinary investors to those with privileged access. This case illustrates that mechanism with unusual precision.

• Wang purchased 160,430 shares of C4 at an average price of $1.91 per share, totaling approximately $306,314. Retail investors who bought at the same time did so without knowing what Wang knew. When the stock hit $5.01 on December 14, 2023, those same retail investors who bought alongside Wang paid a price that reflected uncertainty the SEC alleges Wang had already resolved for himself.
• Wang spread his purchases across four accounts, including a joint account held with his wife and a corporate account under Precision Clinical Consulting. This multi-account structure obscures the total position from any single brokerage’s surveillance system, a tactic that gives sophisticated actors a structural advantage over single-account retail traders who have no such options.
• The use of a corporate entity, Precision Clinical Consulting, to hold brokerage assets and then file for dissolution in February 2025, while the SEC complaint was not yet filed, illustrates the tools available to those who can afford to structure their finances across multiple legal entities. A working-class retail investor has no equivalent mechanism for distancing themselves from a trading account.
• The SEC is seeking disgorgement of profits plus civil monetary penalties. Even if Wang pays the full amount, the damage to market fairness is not reversed. Every retail investor who sold C4 shares during the period Wang was buying, without access to the same information, participated in a transaction that was tilted against them by design.

The “Cost of a Life” Metric: What $489,739 Actually Means

What Wang Agreed To vs. What the SEC Alleges He Did

What Now: Who to Watch and What to Do

The SEC filed this complaint on January 14, 2026. The case is active in the U.S. District Court for the District of Massachusetts under Case No. 1:26-cv-10140. No plea or settlement has been publicly reported as of the filing date. The following individuals and entities are named in the complaint.

Named Defendants

• Hong Wang (a.k.a. “John Wang”): Defendant, alleged to have conducted all trades across all four accounts. The SEC seeks a permanent injunction against him, full disgorgement of profits, and civil monetary penalties.
• Precision Clinical Consulting, LLC: Co-defendant. A New Jersey LLC formed in 2008, dissolved February 2025. Still holds assets in an active brokerage account. Subject to disgorgement of ill-gotten gains jointly and severally with Wang.

SEC Attorneys of Record

• Thomas P. Smith, Jr.: Attorney for Plaintiff, SEC New York Regional Office
• Sandeep Satwalekar: Attorney for Plaintiff, SEC New York Regional Office
• Peter A. Mancuso: Lead contact attorney, SEC New York Regional Office. Contact: (212) 336-5562 / mancusope@sec.gov
• William T. Conway III: Attorney for Plaintiff, SEC New York Regional Office

Regulatory Watchlist

• U.S. Securities and Exchange Commission (SEC): The agency bringing this case. Its Enforcement Division investigates and prosecutes insider trading violations. Public tip line: sec.gov/tcr
• Financial Industry Regulatory Authority (FINRA): Monitors brokerage account activity for suspicious trading patterns. The multi-account structure in this case is exactly the pattern FINRA’s surveillance systems are designed to flag. Investor complaint center: finra.org/investors
• U.S. Department of Justice (DOJ): Can pursue criminal charges for insider trading in parallel with the SEC’s civil complaint. In high-profile cases, criminal referrals from the SEC to the DOJ are common.
• New Jersey Division of Consumer Affairs: Precision Clinical Consulting filed for dissolution in New Jersey. State regulators have concurrent jurisdiction over business conduct.

What You Can Do

• Report suspicious trading activity: The SEC’s Tips, Complaints, and Referrals portal (sec.gov/tcr) allows anyone to report potential securities violations. The SEC’s whistleblower program offers financial awards for tips that lead to successful enforcement actions of over $1 million.
• Demand stronger clinical trial data controls: Contact your congressional representatives and ask them to support legislation requiring stricter compartmentalization of clinical trial data access, with audit trails for every person who downloads patient response data.
• Support patient advocacy organizations: Multiple myeloma and non-Hodgkin lymphoma patient groups rely on the integrity of clinical trial data to advocate for drug approvals. Organizations like the Multiple Myeloma Research Foundation (MMRF) and the Lymphoma Research Foundation track trial progress and deserve public support, especially when trials are caught in legal crossfire.
• Push for structural reforms in consulting contracts: Clinical research organizations should be required to implement real-time brokerage activity monitoring for all contractors with MNPI access, identical to the obligations placed on company insiders. Current law permits gaps in enforcement at the contractor level that this case exploits.
• Mutual aid for affected investors: If you held or traded C4 Therapeutics (NASDAQ: CCCC) stock between November 20 and December 14, 2023, consult a securities attorney about whether you may be eligible to participate in disgorgement proceedings or related civil actions.